Published in J Gen Virol on November 01, 1986
Related functional domains in virus DNA polymerases. EMBO J (1987) 3.35
Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc Natl Acad Sci U S A (1988) 2.27
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother (2010) 1.73
Isolation and characterization of herpes simplex virus mutants containing engineered mutations at the DNA polymerase locus. J Virol (1990) 1.67
Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol (2003) 1.08
Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions. J Virol (1989) 0.85
Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses. Can J Vet Res (1990) 0.75
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19
Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature (1987) 4.45
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Related functional domains in virus DNA polymerases. EMBO J (1987) 3.35
The replication of bacteriophage phi X174 DNA in vitro. Temperature effects on repair synthesis and displacement synthesis. Biochim Biophys Acta (1971) 3.07
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1994) 3.07
High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol (1995) 3.04
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol (1989) 2.40
AIDS virus reverse transcriptase defined by high level expression in Escherichia coli. EMBO J (1987) 2.37
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother (1980) 2.17
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15
Herpes simplex virus latency: the cellular location of virus in dorsal root ganglia and the fate of the infected cell following virus activation. J Gen Virol (1980) 2.07
Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med (1998) 2.07
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature (1981) 2.03
Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol (1980) 2.01
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother (1998) 1.89
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol (1995) 1.80
Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol (1991) 1.80
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture. Antimicrob Agents Chemother (1994) 1.79
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother (2000) 1.75
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine. J Biol Chem (1992) 1.75
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS (2001) 1.73
Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol (1986) 1.69
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Lett (1991) 1.69
Introduction of the herpes simplex virus thymidine kinase gene into mouse cells using virus DNA or transformed cell DNA. Cell (1978) 1.69
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1993) 1.56
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem (1996) 1.39
HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. Biochemistry (1988) 1.38
Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis (1994) 1.35
Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol (1989) 1.33
Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase. J Biol Chem (1983) 1.31
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther (2001) 1.30
Virus drug-resistance: mechanisms and consequences. Antiviral Res (1984) 1.29
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis (1998) 1.26
Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings. J Antimicrob Chemother (2010) 1.23
Specificity of the immune response of mice to herpes simplex virus glycoproteins B and D constitutively expressed on L cell lines. J Gen Virol (1987) 1.23
Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. J Gen Virol (1983) 1.22
Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol (2001) 1.20
Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. J Virol (1988) 1.20
The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis (1981) 1.20
Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance. J Virol (1994) 1.17
3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci U S A (1998) 1.14
Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. Virology (1985) 1.13
Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J Virol (2002) 1.10
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis (1996) 1.05
Cooperative effects between two acyclovir resistance loci in herpes simplex virus. J Virol (1984) 1.01
Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrob Agents Chemother (1986) 1.01
The detection of virus DNA sequences in a herpes type 2 transformed hamster cell line (333-8-9). Int J Cancer (1976) 0.99
RNA-RNA hybridisation using 125I-labelled RNA from tobacco necrosis virus and its satellite. Nature (1974) 0.98
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (2002) 0.98
Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant. J Virol (1982) 0.97
Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol (1993) 0.97
Heat inactivation of vaccinia virus particle-associated functions: properties of heated particles in vivo and in vitro. J Virol (1978) 0.94
Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS (1997) 0.93
Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells. J Gen Virol (1980) 0.92
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. J Antimicrob Chemother (2013) 0.91
Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother (2001) 0.90
Latency and acquired resistance--problems in chemotherapy of herpes infections. Pharmacol Ther (1983) 0.88
Extraction of RNA from mammalian tissue culture cells. Anal Biochem (1974) 0.86
Letter: 3'-Terminal oligonucleotide fragments of tobacco rattle virus ribonucleic acids. J Mol Biol (1973) 0.85
The structure of the DNA of bacteriophage phiX174. VI. Pyrimidine sequences in the complementary strand of the replicative form. J Mol Biol (1970) 0.84
Adenovirus late sequences linked to herpes simplex virus thymidine kinase may be introduced into eukaryotic cells and transcribed. Nucleic Acids Res (1981) 0.81
Isolation and characterization of acyclovir-resistant strains of herpes simplex virus. Am J Med (1982) 0.80
Construction of a herpes simplex virus/varicella-zoster virus (HSV/VZV) thymidine kinase recombinant with the pathogenic potential of HSV and a drug sensitivity profile resembling that of VZV. J Gen Virol (1995) 0.80
Analysis of the role of the cysteine 171 residue in the activity of herpes simplex virus type 1 thymidine kinase by oligonucleotide-directed mutagenesis. J Gen Virol (1987) 0.80
Closing in on HIV drug resistance. Nat Struct Biol (1999) 0.79
Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors. J Antimicrob Chemother (1989) 0.78
Properties of cells carrying the herpes simplex virus type 2 thymidine kinase gene: mechanisms of reversion to a thymidine kinase-negative phenotype. J Virol (1980) 0.77
Patterns of transcription of messengers containing poly A in vaccinia virus-infected cells. J Gen Virol (1974) 0.77
A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Med (2014) 0.77
The clinical significance of antiviral drug resistance. Res Virol (1992) 0.76
The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Res Hum Retroviruses (1999) 0.76
Bent and broken femoral prostheses following total hip replacement: a case report. Aust N Z J Surg (1978) 0.75